Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · IEX Real-Time Price · USD
0.591
-0.024 (-3.90%)
At close: Jul 19, 2024, 4:00 PM
0.600
+0.009 (1.51%)
Pre-market: Jul 22, 2024, 7:02 AM EDT
Organovo Holdings Revenue
In the fiscal year ending March 31, 2024, Organovo Holdings had annual revenue of $109.00K. Revenue in the quarter ending March 31, 2024 was $29.00K.
Revenue (ttm)
$109.00K
Revenue Growth
-70.54%
P/S Ratio
77.92
Revenue / Employee
$5,450
Employees
20
Market Cap
8.49M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Mar 31, 2021 | 0 | - | - |
| Mar 31, 2020 | 2.20M | -895.00K | -28.96% |
| Mar 31, 2019 | 3.09M | -1.51M | -32.85% |
| Mar 31, 2018 | 4.60M | 373.00K | 8.82% |
| Mar 31, 2017 | 4.23M | 2.75M | 185.23% |
| Mar 31, 2016 | 1.48M | 912.00K | 159.72% |
| Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
| Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
| Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
| Dec 31, 2011 | 969.00K | 366.00K | 60.70% |
| Dec 31, 2010 | 603.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Molecular Templates | 31.76M |
| Zhongchao | 19.43M |
| Vivos Therapeutics | 13.36M |
| iCoreConnect | 9.03M |
| Syra Health | 6.08M |
| Kineta | 5.16M |
| Bionomics | 15.00K |
ONVO News
- 3 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 5 days ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 2 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 2 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire
- 2 months ago - Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering - GlobeNewsWire
- 3 months ago - Organovo's fatty liver disease drug meets main goal in mid-stage study - Reuters
- 3 months ago - Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo - GlobeNewsWire
- 6 months ago - Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress - GlobeNewsWire